Asia
Shanghai’s C-Bridge Capital plans to raise $650M for its third healthcare PE fund, just six months after closing its second fund with $400M.
The shareholders of JHL Biotech voted to approve the company’s voluntary delisting from the Taiwan stock exchange.
NCPC GeneTech, the biotech division of North China Pharma, in-licensed China rights for a biosimilar to a second-gen renal anemia treatment from South Korea’s CJ Healthcare.
The company plans to raise $30 million by offering 4.3 million shares at a price range of $6 to $8.
Celltrion are down more than 5 percent after the company announced it received a warning letter from the FDA after the regulatory agency inspected a company drug manufacturing facility.
In addition, Ping An formed a strategic partnership with TytoCare to lead the company’s expansion into China, probably through Ping An’s Good Doctor mobile app.
ARMO BioSciences completed a $128M IPO in the US after raising capital from China VCs;
Despite some safety concerns such as severe diarrhea, the FDA approved Puma’s breast cancer drug Nerlynx in July 2017.
New kid on the block Tmunity just banked a series A funding round worth $100M.
Sanofi has announced major restructuring, which will involve about 400 job cuts in the U.S.
PRESS RELEASES